Ask AI
ProCE Banner Activity

CE / CME

TYK2 Inhibition in Plaque Psoriasis: Expert Answers to Your Frequently Asked Questions

Clinical Thought

Advances in therapeutic development have expanded the range of treatment options available to patients with psoriasis. TYK2 inhibitors offer the potential to address persistent unmet needs in plaque psoriasis by offering safe and efficacious oral therapies to those with moderate to severe disease. Explore expert perspectives in this commentary to learn how to best leverage novel TYK2 inhibitors via patient selection, treatment sequencing, and considerations for the concomitant use of topical therapies when treating patients with plaque psoriasis.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Physicians: maximum of 0.25 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: November 19, 2026

Expiration: November 18, 2027

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for dermatology HCPs, including dermatologists, nurse practitioners (NPs), physician associates (PAs), and other HCPs who care for patients with PsO.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Psoriasis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review the unmet medical needs in the management of moderate to severe psoriasis, including significant under-treatment/nonadherence and its impact, comorbidities, and the need for more effective and well-tolerated treatments

  • Differentiate the efficacy, safety, and selectivity profiles of treatments targeting TYK2 versus JAK1, JAK2, and JAK3 signaling pathways in moderate to severe psoriasis

  • Summarize the recent and ongoing clinical trial data for current and emerging oral small molecule treatments for patients with moderate to severe psoriasis

  • Identify patients with psoriasis who would be appropriate candidates for oral small molecule treatment based on patient preference, efficacy, and safety

Financial Disclosures

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

April W. Armstrong, MD, MPH: researcher: AbbVie, Alumis, Bristol Myers Squibb, Galderma, Janssen, Novartis, Takeda; consultant/advisor/speaker: AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, Leo, Lilly, Novartis, Ortho Derm, Pfizer, Regeneron, Sanofi, UCB; data and safety monitoring board: Boehringer Ingelheim.

Melinda Gooderham, MD, MSc, FRCPC: consultant/advisor/speaker (paid to institution): AbbVie, Amgen, Apogee, Apollo, Arcutis, Bausch Health, Boehringer Ingelheim, Coultreon, Expedition, Galderma, GSK, Jamp, Janssen, Leo, Lilly, L’Oreal, Novartis, Organon Canada, Pfizer, Regeneron, Sanofi Genzyme, Sun, Takeda, UCB, Union; researcher (paid to institution): AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Aristea, Attovia, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermira, Galderma, GSK, Incyte, Insmed, Jamp, Janssen, Leo, Lilly, Meiji Seika, Merck, MoonLake, Nektar, Novartis, Organon Canada, Oruka, Pfizer, Q32 Bio, Regeneron, Reistone, Sanofi Genzyme, Sun, Takeda, Tarsus, UCB, Ventyx, Vyne.

Linda Stein Gold, MD: consultant/advisor/speaker: AbbVie, Amgen, Alumis, Arcutis, Bristol Myers Squibb, Galderma, Johnson & Johnson, Kymara, Leo, Organon, Ortho, Regeneron, Sanofi.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 19, 2026, through November 18, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until November 18, 2027. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.